___

• Siegel R, Ma J, Zou Z, and Jemal A . Cancer statistics. CA Cancer J Clin.2014;64:9-29.
• Hillman GG, Lonardo F, Hoogstra DJ, Rakowski J, Yunker CK, Joiner MC,Dyson G, Gadgeel S, Singh-Gupta V. Axitinib Improves Radiotherapy inMurine Xenograft Lung Tumors. Transl Oncol. 2014;7:400-409.
• Bilir C, Balık MS, Kızılkaya B, Yıldırım S, Gemez S, Bilir F. Serum LactateDehydrogenase Levels May Predict Fentanyl Usage in Patients withMetastatic Cancers for The Treatment of Cancer Related Pain. J hum
• rhythm. 2016;2(2):78-82.
• de Geus-Oei L, van Krieken JH, Aliredjo R, Krabbe PF, Frielink C, VerhagenAF, Boerman OC, Oyen WJ. Biological correlates of FDG uptake in nonsmallcell lung cancer. Lung Cancer. 2007; 55: 79–87.
• Kieninger A, Welsh R, Bendick P, Zelenock G, Chmielewski GW. Positronemissiontomography as a prognostic tool for early-stage lung cancer. AmJ Surg. 2006; 191:433-436.
• Vesselle H1, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallires E, WoodDE. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucoseuptake by positron emission tomography. Clin Cancer Res. 2000;6:3837-3844.
• Higashi K1, Ito K, Hiramatsu Y, Ishikawa T, Sakuma T, Matsunari I, KugaG, Miura K, Higuchi T, Tonami H, Yamamoto I. 18F-FDG uptake by primarytumor as a predictor of intratumoral lymphatic vessel invasion and lymphnode involvement in non-small cell lung cancer: analysis of a multicenterstudy. J Nucl Med. 2005;46:267-273.
• Zhang ZJ, Chen JH, Meng L, Du JJ, Zhang L, Liu Y, Dai HH. 18F-FDG uptakeas a biologic factor predicting outcome in patients with resected non-smallcelllung cancer. Chin Med J (Engl). 2007;120:125-131.
• Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM, Lee DS, Lee
• MC, Han SK, Shim YS. Determination of the prognostic value of [(18)F]
• fluorodeoxyglucose uptake by using positron emission tomography in
• patients with non-small cell lung cancer. 2002;23:865-870.
• Viberti L, Papotti, M, Abbona G.C, Celano,A, Filosso PL, Bussolati G. Valueof Ki-67 immunostaining in preoperative biopsiesof carcinomas of the lung.Hum. Pathol.1997;28:189-192.
• Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging:
• a method to assess the proliferative activity of human cancer in vivo.
• Comparison with DNA flow cytometry in head and neck tumors. Cancer
• (Phila.). 1988;61:1776–1781.
• Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, ZiglerS, Oberdorfer F, Rudat V, VanKaick G. Glucose uptake, perfusion, andcell proliferation in head and neck tumors: relation of positron emissiontomography to flow cytometry. J. Nucl.Med.1991;32: 1548-1555.
• Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi P J, Soderstrom KO,Bergman J, Haaparanta M, Ruotsalainen U, Solin O. Increased glucosemetabolism in untreated non-Hodgkin’s lymphoma: a study with positronemission tomography and flüorine-18-fluorodeoxyglucose. Blood.
• ;86:3522–3527.
• Kaida H, Kawahara A, Hayakawa M, Hattori S, Kurata S, Fujimoto K, AzumaK, Hirose Y, Takamori S, Hiromatsu Y, Nakashima T, Fujita H, Kage M,Hayabuchi N, Ishibashi M. The difference in relationship between 18F-FDGuptake and clinicopathological factors on thyroid, esophageal, and lungcancers. Nucl Med Commun. 2014;35:36-43.
• Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, VallièresE, Wood DE. Relationship between non-small cell lung cancer FDG uptakeat PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol.2008;3:971-978.
• Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, YamazakiK, Uno K, Kobayashi T, Goya T. [F-18]Fluorodeoxyglucose positron emissiontomography can predict pathological tumor stage and proliferative activitydetermined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin
• Oncol. 2006;36:403-409.
• Zhou M, Sun T, Xing X, Yang J. The Correlation between FDG PET/CT
• Imaging and Molecule Makers in Non-Small Cell Lung Cancer. Zhongguo
• Fei Ai Za Zhi. 2009 20;12:172-175.
• Araz O, Demirci E, Ucar EY, Calik M, Karaman A, Durur-Subasi I, Orsal E,Subasi M, Daloglu F, Akgun M. Roles of Ki-67, p53, transforming growthfactor-
• Sasaki M, Sugio K, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K,Hayashi K, Shioyama Y, Sakai S, Honda H. Alterations of tumor suppressorgenes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer.Ann Nucl Med. 2003;17:189-96.
• Duan XY, Wang W, Wang JS, Shang J, Gao JG, Guo YM. Fluorodeoxyglucosepositron emission tomography and chemotherapy-related tumor markerexpression in non-small cell lung cancer. BMC Cancer. 2013;13:546.
• Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the
• standardized uptake value in FDG-PET with the expression level of cellcycle-related molecular biomarkers in resected non-small cell lung cancers.Ann Thorac Cardiovasc Surg. 2009;15:304-10.
• Tabata K, Tanaka T, Hayashi T, Hori T, Nunomura S, Yonezawa S, FukuokaJ. Ki-67 is a strong prognostic marker of non-small cell lung cancer whentissue heterogeneity is considered. BMC Clin Pathol. 2014;14:23.
• Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, et al. p53: a
• frequent target for genetic abnormalities in lung cancer. Science 1989;
• : 491-494.
• d'Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ. Prevalenceof in vitro extreme chemotherapy resistance in resected nonsmall-cell lungcancer. Ann Thorac Surg. 2006;81:440-446.
• Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD. p53-dependent regulation of MDR1 gene expression causes selective resistanceto chemotherapeutic agents. Proc Natl Acad Sci USA. 1997;94:11037-11042.